Literature DB >> 23103995

Cystic fibrosis therapy: a community ecology perspective.

Douglas Conrad1, Matthew Haynes, Peter Salamon, Paul B Rainey, Merry Youle, Forest Rohwer.   

Abstract

Current therapy for cystic fibrosis (CF) focuses on minimizing the microbial community and the host's immune response through the aggressive use of airway clearance techniques, broad-spectrum antibiotics, and treatments that break down the pervasive endobronchial biofilm. Antibiotic selection is typically based on the susceptibility of individual microbial strains to specific antibiotics in vitro. Often this approach cannot accurately predict medical outcomes because of factors both technical and biological. Recent culture-independent assessments of the airway microbial and viral communities demonstrated that the CF airway infection is considerably more complex and dynamic than previously appreciated. Understanding the ecological and evolutionary pressures that shape these communities is critically important for the optimal use of current therapies (in both the choice of therapy and timing of administration) and the development of newer strategies. The climax-attack model (CAM) presented here, grounded in basic ecological principles, postulates the existence of two major functional communities. The attack community consists of transient viral and microbial populations that induce strong innate immune responses. The resultant intense immune response creates microenvironments that facilitate the establishment of a climax community that is slower-growing and inherently resistant to antibiotic therapy. Newer methodologies, including sequence-based metagenomic analysis, can track not only the taxonomic composition but also the metabolic capabilities of these changing viral and microbial communities over time. Collecting this information for CF airways will enable the mathematical modeling of microbial community dynamics during disease progression. The resultant understanding of airway communities and their effects on lung physiology will facilitate the optimization of CF therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103995      PMCID: PMC3604065          DOI: 10.1165/rcmb.2012-0059PS

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  52 in total

1.  The emergence and maintenance of diversity: insights from experimental bacterial populations.

Authors: 
Journal:  Trends Ecol Evol       Date:  2000-06       Impact factor: 17.712

Review 2.  The interaction of phage and biofilms.

Authors:  Ian W Sutherland; Kevin A Hughes; Lucy C Skillman; Karen Tait
Journal:  FEMS Microbiol Lett       Date:  2004-03-12       Impact factor: 2.742

3.  A fractal analysis of the radial distribution of bronchial capillaries around large airways.

Authors:  Joseph C Anderson; Albert L Babb; Michael P Hlastala
Journal:  J Appl Physiol (1985)       Date:  2004-11-12

4.  Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

Authors:  Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

5.  Adaptive radiation in a heterogeneous environment.

Authors:  P B Rainey; M Travisano
Journal:  Nature       Date:  1998-07-02       Impact factor: 49.962

6.  Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms.

Authors:  G W Hanlon; S P Denyer; C J Olliff; L J Ibrahim
Journal:  Appl Environ Microbiol       Date:  2001-06       Impact factor: 4.792

Review 7.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

8.  Pulmonary blood flow remains fractal down to the level of gas exchange.

Authors:  R W Glenny; S L Bernard; H T Robertson
Journal:  J Appl Physiol (1985)       Date:  2000-08

9.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

10.  Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities.

Authors:  Christopher J van der Gast; Alan W Walker; Franziska A Stressmann; Geraint B Rogers; Paul Scott; Thomas W Daniels; Mary P Carroll; Julian Parkhill; Kenneth D Bruce
Journal:  ISME J       Date:  2010-12-09       Impact factor: 10.302

View more
  54 in total

Review 1.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.

Authors:  Lindsay J Caverly; John J LiPuma
Journal:  Expert Rev Respir Med       Date:  2018-09-03       Impact factor: 3.772

2.  Contrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages.

Authors:  Alex Betts; Oliver Kaltz; Michael E Hochberg
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

3.  Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms.

Authors:  Alexa A Pragman; John P Berger; Bryan J Williams
Journal:  Clin Pulm Med       Date:  2016-03

Review 4.  How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?

Authors:  Geraint B Rogers; Kenneth D Bruce; Lucas R Hoffman
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

Review 5.  Host-pathogen interplay in the respiratory environment of cystic fibrosis.

Authors:  Lael M Yonker; Cristina Cigana; Bryan P Hurley; Alessandra Bragonzi
Journal:  J Cyst Fibros       Date:  2015-03-19       Impact factor: 5.482

Review 6.  The pediatric microbiome and the lung.

Authors:  Michael Tracy; Jonathan Cogen; Lucas R Hoffman
Journal:  Curr Opin Pediatr       Date:  2015-06       Impact factor: 2.856

7.  An investigation of canine leptospiral antibodies in Tokyo and Yokohama. Comparison of Canine Positive rates between rapid microscopic agglutination test and Schüffner-Mochtar test.

Authors:  E Ryu; A Hasegawa; S Saegusa; H Ichiki
Journal:  Int J Zoonoses       Date:  1974-12

Review 8.  Steering Phages to Combat Bacterial Pathogens.

Authors:  James Gurney; Sam P Brown; Oliver Kaltz; Michael E Hochberg
Journal:  Trends Microbiol       Date:  2019-11-16       Impact factor: 17.079

9.  Real-time metabolomics on living microorganisms using ambient electrospray ionization flow-probe.

Authors:  Cheng-Chih Hsu; Mariam S ElNaggar; Yao Peng; Jinshu Fang; Laura M Sanchez; Samantha J Mascuch; Kirsten A Møller; Emad K Alazzeh; Jiri Pikula; Robert A Quinn; Yi Zeng; Benjamin E Wolfe; Rachel J Dutton; Lena Gerwick; Lixin Zhang; Xueting Liu; Maria Månsson; Pieter C Dorrestein
Journal:  Anal Chem       Date:  2013-07-11       Impact factor: 6.986

10.  Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis.

Authors:  Yan Wei Lim; Jose S Evangelista; Robert Schmieder; Barbara Bailey; Matthew Haynes; Mike Furlan; Heather Maughan; Robert Edwards; Forest Rohwer; Douglas Conrad
Journal:  J Clin Microbiol       Date:  2013-11-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.